InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
58,200.01
(
-0.17%
)
Post# of 252498
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119983
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: gofishmarko post# 40627

Thursday, 01/25/2007 10:21:54 PM

Thursday, January 25, 2007 10:21:54 PM

Post# of 252498
Viragen Provides 2007 Outlook: Part II

[VRA issues a PR every time a transgenic hen lays an egg. The avian portion of this PR can be summed up by saying that, after all these years, VRA still has a heck of a lot of work to do to be considered a serious contender in transgenic production of proteins drugs.]

http://biz.yahoo.com/prnews/070125/clth107.html?.v=12

>>
Thursday January 25, 12:00 pm ET

PLANTATION, Fla., Jan. 25 /PRNewswire-FirstCall/ -- The following is Part II of a letter from Charles A. Rice, President and CEO of Viragen, Inc. (Amex: VRA ; VRA.U; VRA.WS) and Viragen International, Inc. (OTC Bulletin Board: VGNI). In addition to these comments, stockholders and potential investors are referred to: the Company's SEC filings, including Form 10-K and Form 10-Q (Annual and Quarterly Reports); press releases; website; and other publicly disseminated information, which is available free of charge upon request by contacting the Company. Part I of Mr. Rice's letter was issued yesterday.

Dear valued Stockholder,

In Part I of my letter, I focused on our plans for Multiferon®, which will remain a priority for the Company due to its potential to generate licensing and sales revenues in the immediate term. Now I will review our plans for our anti-cancer candidates and the OVA(TM) System. [I omitted the cancer stuff—please see the link above if interested.]

OVA(TM) System: Avian Transgenic Biomanufacturing

The concept of efficiently and cost-effectively producing therapeutic proteins in the eggs of transgenic chickens is certainly revolutionary, and the OVA(TM) System is receiving much attention with the successful production of three functional protein-based drugs in hen's eggs thus far. We continue to work closely with our partners at Roslin Institute, creators of "Dolly the Sheep", to make this vision a reality. Earlier this week, we reported the recovery of our third OVA(TM)-expressed protein, interferon alpha-2a, and we expect to report on a fourth protein later this year.

With each OVA(TM)-expressed protein, we are evaluating the consistency, quality and quantities of each product candidate expressed over multiple generations of hens. These data will help us determine which types of proteins are best suited for this manufacturing platform. The next important step for our development plan will be to select a first product candidate that we will take into production and into the registration process. No kidding.]

While there is considerable industry and public interest in the OVA(TM) System, this is still pioneering science with much to prove. It appears likely that we should have an OVA(TM)-expressed product candidate at a more advanced stage in clinical development, at least through the initial regulatory processes in the U.S. or the EU, in order to generate realistic licensing opportunities. This will require significant additional funding and a number of years of work by our avian transgenics team. However, we will strive to choose a first commercial product candidate that permits us to take advantage of "expedited" regulatory processes that may be available to us, so that the overall time required can be reduced.

…In Closing:

The Management of Viragen expresses our sincere thanks to our stockholders, for your patience and perseverance, even in the face of dissatisfaction with our share valuation and past sales results. We have positioned our projects and resources in expectation that 2007 and future years will yield vastly improved results.

Our success is dependent upon our ability to secure adequate funding to support our activities. We are exploring various alternatives including financings, grants and new strategic initiatives. Additionally, we aim to execute a funding strategy that will return Viragen to compliance with the Amex's maintenance criteria, as we must do so by March 20, 2007 to remain compliant with the plan we submitted to the Amex. While we intend to become compliant by this deadline, our ability to do so will be dependent upon the availability of funding on satisfactory terms and other factors outside of our control, and we cannot provide assurances that our efforts in this regard will be successful.

Our plans are ambitious, but also flexible, so that we can react quickly should changes be necessary, and we are highly confident that we will be able to build the kind of Company our stockholders can be proud of.
<<

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up